Brokers Issue Forecasts for Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Shattuck Labs in a report released on Thursday, March 27th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.40) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($2.00) EPS.

A number of other research analysts also recently issued reports on the stock. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday. Finally, Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $1.06 on Monday. The company has a market capitalization of $50.37 million, a price-to-earnings ratio of -0.69 and a beta of 1.66. Shattuck Labs has a one year low of $0.94 and a one year high of $11.76. The stock has a 50-day simple moving average of $1.24 and a 200 day simple moving average of $1.46.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.

Institutional Investors Weigh In On Shattuck Labs

Several large investors have recently made changes to their positions in the company. FMR LLC increased its position in Shattuck Labs by 0.4% in the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after acquiring an additional 26,460 shares during the period. MetLife Investment Management LLC grew its stake in shares of Shattuck Labs by 129.1% in the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares in the last quarter. Atom Investors LP acquired a new position in shares of Shattuck Labs during the third quarter valued at $35,000. Benjamin Edwards Inc. bought a new stake in shares of Shattuck Labs during the third quarter valued at about $61,000. Finally, Readystate Asset Management LP acquired a new stake in Shattuck Labs in the third quarter worth about $39,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.